Long acting GLP-1 receptor agonist (injectable)
Dulaglutide flexible dose injection once weekly
DULA_SC_FLEX_0p75-1p5_QW
Related
- All doses pooled: Dulaglutide injection
- Dulaglutide 1.0 mg injection once weekly
- Dulaglutide 1.5 mg subcutaneous once weekly
- Dulaglutide 3.0 mg subcutaneous once weekly
- Dulaglutide 4.5 mg subcutaneous once weekly
- Dulaglutide 0.25 mg injection once weekly
- Dulaglutide 0.5 mg injection once weekly
- Dulaglutide 0.75 mg subcutaneous once weekly
- Dulaglutide 2.0 mg injection once weekly
- Dulaglutide 0.1 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Basal bolus insulin | HR 0.28 (0.02 to 2.61) | 0.73 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.48 (0.01 to 34.34) | 0.60 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 8.83 (0.68 to 255) | 0.23 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.80 (0.10 to 113) | 0.38 |